Document is current
Any future updates will be listed below
-
Authors
Spohn, Simon K. B. https://orcid.org/0000-0003-2727-8005
Farolfi, Andrea
Schandeler, Sarah
Vogel, Marco M. E.
Ruf, Juri
Mix, Michael
Kirste, Simon
Ceci, Francesco
Fanti, Stefano
Lanzafame, Helena
Serani, Francesca
Gratzke, Christian
Sigle, August
Combs, Stephanie E.
Bernhardt, Denise
Gschwend, Juergen E.
Buchner, Josef A.
Trapp, Christian
Belka, Claus
Bartenstein, Peter
Unterrainer, Lena
Unterrainer, Marcus
Eiber, Matthias
Nekolla, Stephan G.
Schiller, Kilian
Grosu, Anca L.
Schmidt-Hegemann, Nina-Sophie
Zamboglou, Constantinos
Peeken, Jan C.
-
Funding
Funding for this research was provided by:
DKTK (SKBS, CZ received funding by the DKTK as part of the IMRPO-REC project.)
Universitätsklinikum Freiburg
- License Information
-
More Information
Article History
Received: 2 May 2022
Accepted: 1 August 2022
First Online: 19 August 2022
Declarations
:
: ME reports prior consulting activities for BED, Novartis, Telix, Progenics, Bayer, Point Biopharma, and Janssen and a patent application for rhPSMA. All other authors declare no conflicts of interest regarding this study.
